The oncology drug development firm Erasca, Inc. (NASDAQ: ERAS) is now confronting a securities fraud class action lawsuit. Investors allege the company misled them regarding preclinical data comparisons for its lead drug candidate, ERAS-0015. The deadline for investors to apply to serve as lead plaintiff is August 10, 2026.

The legal action stems from two significant negative disclosures made on consecutive days, April 27 and 28, 2026. On April 27, the company revealed it had received a letter from a lawyer representing competitor Revolution Medicines. The letter accused ERAS-0015 of infringing a U.S. patent and claimed Erasca had made "improper comparisons" in its public disclosures between ERAS-0015 and RevMed's drug RMC-6236, involving allegations of trade secret misappropriation. After the market closed that same day, Erasca released preliminary Phase 1 clinical data for ERAS-0015, disclosing that a patient treated with a 24 mg dose had died after a pneumonia event progressed to a Grade 5 adverse event approximately one month post-dosing. The company acknowledged that its comparisons of ERAS-0015 to other candidates were "not based on any head-to-head clinical trial" and that such comparisons "have inherent limitations."

These announcements triggered a severe stock price decline. Over two trading days, the share price plummeted from $21.49 on April 24 to close at $9.90 on April 28, representing a cumulative drop of approximately 54% and erasing about $2.8 billion in market value.

The lawsuit claims that during the class period from January 14, 2025, to April 26, 2026, Erasca and its executives promoted ERAS-0015 as a potential "best-in-class" therapy with purportedly superior preclinical results. The complaint alleges the company failed to disclose that these comparisons lacked a sound basis and exposed the company to risks of patent and trade secret disputes.